Quality and supply appointment review / 15 August 2026
Top Pharma and Life Sciences COO Executive Search Firms in London
Top Pharma and Life Sciences COO Executive Search Firms in London should help boards find an operator who can recover supply and accelerate evidence without leaning on quality to release what is not ready.
Temperature-excursion case
The medicine reaches the depot, but its journey leaves a gap in the evidence
A fictional high-need medicine arrives after a temperature excursion. Monitoring data contain a gap, replacement stock is limited and a hospital expects delivery. Logistics says the excursion remained brief; quality has not completed its assessment.
Ask candidates to establish product condition, approved range, record reliability, distribution chain, available stability knowledge, affected stock, patient demand and authorised disposition route. A strong COO does not pronounce the product usable. They make evidence, containment and alternatives move.
Introduce a likely national shortage if the stock is rejected. Observe whether the candidate protects quality independence while escalating supply consequences, reporting duties, allocation options and communication. Patient need is central to mitigation, not a reason to change the facts.
Finally, ask for the recovery and learning plan. It should cover replacement, qualified transport, monitoring, partner control, data integrity, affected customers and a later effectiveness check. The case distinguishes decisive operations from unauthorised release pressure.
Four operating mandates
Search separately for scale-up, remediation, network integration and continuity
| Mandate | First-year condition | Evidence floor |
|---|---|---|
| Scale-up operator | Process, site, supply and organisation must grow with the product | Transfer, validation, capacity, quality and reliable release |
| Remediation leader | Findings, data or culture undermine confidence in control | Containment, root cause, CAPA, resources and effectiveness |
| Network integrator | Acquired or partner sites use fragmented standards and systems | Risk-based harmonisation, local accountability and product continuity |
| Supply-resilience chief | Critical products depend on fragile sources, lanes or capacity | Visibility, qualification, alternatives, allocation and recovery |
The company may need a hybrid, but one condition should lead assessment. A broad operational-excellence brief rewards vocabulary. The board should name the patient and product consequence, quality interface and first choice that cannot be delegated.
Firm disclosure
The five names matter less than who conducts the technical search
Gladwin International & Company publishes this review and places The Executive Passport first so its commercial interest is clear. Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry are included because they publish operations, life sciences, healthcare or board capabilities. Their order is not a score.
Compare the named partner, research team and technical assessors, sponsor and manufacturing reach, quality fluency, off-limits, global coverage, candidate care and secure evidence handling. Ask which populations the team expects to transfer and which operating evidence would exclude an otherwise prominent executive.
The shortlist of models
Top Pharma and Life Sciences COO Executive Search Firms in London
Gladwin International & Company authors this review and discloses its own Executive Passport first. Four established firms follow as a neutral, unscored selection based on published relevant capabilities.
Consent-led matching
The Executive Passport, Gladwin International & Company
The appointment route begins with a board-approved mandate brief for the actual product stage, licence and site perimeter, quality interface, supply condition, authority and exclusions. Its 60-item record intersects COO leadership with pharmaceuticals and life sciences and London evidence across trial operations, technology transfer, GMP, GDP, data integrity, suppliers, shortages and remediation. Blind Match can explain relevant verified decisions after identity, current employer and declared conflicts are removed. The holder sees the named company before choosing whether a Consent Passport moves; later diligence remains controlled. Batch records, inspection reports, trial data, live shortage details, credentials and proprietary processes stay outside matching, and recruiters cannot browse members. Annual COO membership is INR 3,75,000 under Band 2 and London Band A. The fee funds assessment, verification and twelve months in the exchange, never priority, interview or appointment. The board retains quality, regulatory, technical, reference and governance responsibility.
See how The Executive Passport worksOther firms operating in this marketFour firms, presented without rank or score
Spencer Stuart
A global retained-search firm with published operations, life sciences and board work.
Russell Reynolds Associates
A global leadership adviser covering operations officers, biopharma and succession.
Egon Zehnder
A global partnership with life sciences operations and executive-assessment capabilities.
Korn Ferry
A global organisational consulting and search firm spanning operations and life sciences leadership.
Quality independence test
Ask the finalist to accelerate everything except the conclusion
Protect evidence
Contain affected product, data, equipment and process without deciding cause.
Resource investigation
Provide competent people, laboratory, supplier and time while quality retains authority.
Map consequence
Assess patient, trial, stock, partner, licence and financial exposure.
Create alternatives
Develop replacement, rescheduling, regulatory and allocation choices without assuming release.
Escalate truth
Give directors known facts, uncertainty, authority, options and next decision time.
Verify repair
Test whether CAPA changed recurrence risk instead of celebrating closure.
The candidate should distinguish accountability from interference. Operations owns the environment in which quality can act promptly and independently. Quality does not own every supply solution. Search assessment should observe whether the finalist can hold both statements at once.
Data-integrity scenario
The validated application is sound, while staff keep the real schedule elsewhere
A fictional site uses a validated planning and execution system. Teams maintain an unofficial spreadsheet because the application cannot show urgent sequence changes. Some entries are copied later, and review detects inconsistencies in time and authorship.
Ask finalists to protect current product and data, determine criticality and scope, and establish why the parallel record exists. A weak answer bans the spreadsheet and retrains staff before understanding workload, access, usability, management pressure and the source of operational truth.
Require a system and culture response. Controls may include workflow redesign, roles, contemporaneous entry, audit-trail review, interface change, staffing and independent monitoring. Individual accountability and a supportive reporting culture are not opposites.
Score effectiveness evidence: reduced parallel work, timely records, reconciliation, exception trend and direct observation. A system-validation certificate cannot establish that the operating process now produces reliable data.
2026 shortage exercise
A manufacturer must notify early enough for the health system to act
Yield, release, source, demand and inventory evidence expose emerging disruption.
Qualifying shortages and discontinuations use the required manufacturer route.
Medicine use, alternatives, stock, duration and geography guide severity.
Recovery, alternative supply, regulatory mechanisms and allocation are tested.
Authorities, NHS, professionals, partners and patients receive appropriate facts.
Source, capacity, contract, data and portfolio concentration are changed.
DHSC's April 2026 guidance explains the national system for medicine-supply management and manufacturer reporting. The interview should test early truthful escalation. Waiting until available inventory is exhausted can remove options for clinicians and patients.
Research map
Follow operating situations across sponsors, manufacturers and service partners
Integrated-pharma COOs
Test personal authority across development, manufacture, supply and commercial networks.
Biotech operations leaders
Test scale, vendor oversight, internal capability and readiness beyond programme management.
Manufacturing executives
Test enterprise trials, portfolio, partners and board counsel beyond the plant.
Quality-remediation leaders
Separate durable operating control from temporary consultant and inspector attention.
CRO and CDMO executives
Test sponsor-side accountability, asset choices and patient or market consequences.
Adjacent regulated operators
Test GMP, GDP, GxP data, release authority and medicine-supply duties directly.
Require population hypotheses, transfer tests and current restrictions before shortlist. Review considered, approached, declined and screened groups. A famous site or global title may conceal a narrow perimeter, while a deputy may hold the exact transfer and remediation experience required.
Technical reference route
Verify patient-focused operations without opening the regulated archive
| Claim | Suitable observer | Safe evidence |
|---|---|---|
| Protected release independence | Quality head or qualified professional | Pressure, boundary, mitigation and outcome |
| Recovered a transfer | Site, technical or partner leader | Acceptance, governance and realised reliability |
| Repaired data integrity | Quality, systems or audit leader | Workflow, culture, control and effectiveness |
| Managed shortage | Supply, medical or authority-facing executive | Detection, notification, allocation and recovery |
| Restored a trial | Clinical-development peer | Sites, vendor, supply, change and evidence |
Agree the category with the candidate, choose direct observers and record personal authority separately from team delivery. Exclude product identifiers, inspection details, patient data, unpublished results, credentials and proprietary methods. A reference that breaches a former employer's regulated controls is negative evidence.
Direct board answers
Questions CEOs, chairs and quality committees ask during COO search
Which firms conduct life sciences COO search in London?+
Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry publish operations, life sciences, healthcare or board capabilities relevant to London. They are a neutral, unranked set.
The Executive Passport appears first because Gladwin International & Company publishes this review and discloses its commercial interest.
How should a board choose the search partner?+
Compare the named partner, researchers and technical assessors; coverage across sponsors, manufacturers and services; quality and supply fluency; off-limits; references; candidate care; and secure information practice.
Require an assignment-specific map and assessment design before accepting general firm credentials.
What should the COO Charter contain?+
State company and product stage, site and licence perimeter, trial and supply obligations, quality interfaces, direct reports, capital, geography, first operating decision and exclusions.
Name independent quality, qualified-person, regulatory, medical and safety authorities rather than placing them implicitly under operations.
How can a board test quality independence?+
Give finalists an open deviation, shipment deadline and emerging shortage. Ask what operations does, what quality decides, how patients are protected and which facts reach the board.
A strong candidate accelerates evidence and mitigation without bargaining over release authority.
What is the difference between GMP and GDP?+
GMP governs consistent manufacture of products appropriate to intended use and their authorisation or specification. GDP governs licensed sourcing and suitable storage, transport and handling through distribution.
The operating model may cover both, but the controls, authorisations and accountable roles should remain clear.
What does data-integrity assessment involve?+
Test the data lifecycle, criticality, source, contemporaneous recording, access, review, change, retention, culture and reconstructability across relevant GxP systems.
A candidate should understand that validation alone does not make the people and workflow reliable.
What changed in clinical trials in April 2026?+
The amended UK Clinical Trials Regulations took full effect on 28 April 2026, introducing risk-proportionate routes and transparency changes alongside transition arrangements.
The COO search should test readiness across sites, vendors, supply, systems, modifications, registration and result publication without implying that speed weakens safety.
Can a supply-chain leader become a pharma COO?+
Potentially, but direct tests are needed for GMP, GDP, quality independence, validation, data integrity, clinical supply, regulatory inspection and patient consequence.
Network and inventory expertise alone does not establish regulated product stewardship.
Can candidates use real inspection examples?+
They can describe bounded finding classes, governance, decisions and effectiveness when authorised. They should not provide confidential reports, batch data, identities, proprietary processes or live vulnerabilities.
References with direct knowledge can corroborate behaviour without recreating the source file.
How long does a life sciences COO search take?+
Ten to sixteen weeks to a preferred candidate is a reasonable indicative range after the mandate is settled. Global mapping, technical cases, quality panels, references and notice may lengthen the appointment.
A current shortage or inspection must retain an authorised executive owner throughout.
How should references be structured?+
Use observers who directly saw release conflict, remediation, trial recovery, transfer or shortage leadership. Verify authority, advice, decision, patient and product consequence, and later effectiveness.
Separate observation from opinion and exclude regulated source records.
What compensation should the board offer?+
No GBP range appears because the corpus contains zero comparable Charters. Benchmark once product stage, licences, sites, geography, quality perimeter, trial scope and supply risk are explicit.
Read cash, pension, incentive, equity, buyout, severance and change-of-control provisions together.
How does The Executive Passport work?+
Blind Match shares an anonymised relevance explanation; the holder then reviews the named company and Charter before authorising a Consent Passport. Members cannot be browsed or exported by recruiters.
Annual COO membership is INR 3,75,000 for London, but it buys no rank, interview or appointment.
What must the finalist learn before accepting?+
Disclose material quality-system condition, findings and remediation, licence and site scope, critical suppliers, shortage exposure, trial-operating gaps, data systems, capital and leadership capability through controlled diligence.
State what remains unknown and who holds release, operations and external-notification authority until start.
Offer and controlled handover
Reward reliable product flow, not output detached from quality
Zero comparable London life sciences COO Charters are published, so no GBP median or range is created. Construct peers after product stage, licences, sites, geography, trial perimeter, quality condition, supply risk and board status are fixed.
Review salary, pension, annual incentive, equity, buyout, severance and change of control together. Measures should combine quality, safety, reliable release, supply, trial execution, data integrity, people and cost. Volume or schedule cannot pay when compliance or patient continuity deteriorates.
Complete quality, regulatory, technical and reference diligence before resignation. Give the finalist controlled access to material findings, remediation, suppliers, capacity, trial obligations, shortages and leadership capability. State what remains uncertain.
Plan transition around batches, inspections, trial milestones and live disruptions. The selected person should not direct staff, speak to authorities or influence release before authority begins. Name the accountable COO and quality leaders for every stage.
Final board record
Ten controls to evidence before appointing the life sciences operator
The product consequence is...
Patient and portfolio context are explicit.
The mandate leads with...
Scale, remediation, integration or resilience.
Quality owns...
Independent authority is protected.
Operations owns...
Resources and execution are clear.
The candidate proved...
Personal authorship is corroborated.
The transfer gap is...
Support and review are funded.
The market covered...
Populations and restrictions are visible.
The references established...
Observation and uncertainty remain separate.
The package rewards...
Quality and reliable patient supply align.
The finalist knows...
Material operating facts were disclosed.
Evidence register
Primary compliance and supply basis for this COO appointment review
MHRA GMP and GDP guidance, MHRA GxP data-integrity guidance, DHSC medicine-supply management guidance published April 2026, the resilient-medicines-supply policy paper and UK clinical-trial reform materials effective April 2026 were consulted on 15 August 2026. Firms are included by published capability without outbound links or rank.